Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Older NMP1-Mutant/KMT2A-Rearranged AML |   Image Credit: © Oleksandr - stock.adobe.com

Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NMP1/KMT2A-Altered AML

June 12th 2025

Revumenib plus azacitidine and venetoclax yielded high CR rates among older patients with NPM1-mutant/KMT2A-rearranged newly diagnosed AML.

Tetiana Skrypets, MD, PhD, clinical research physician, hematology, Hematology and Cell Therapy Unit, Istituto Tumori “Giovanni Paolo II"

Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL

June 12th 2025

Tetiana Skrypets, MD, PhD, discusses next steps for researching the clinical features and treatment outcomes of older patients with PTCL.

Urothelial Carcinoma |  Image Credit: © Matthieu  - stock.adobe.com

EV-302 Regimen Shows Sustained Efficacy Vs Chemo Across Key Subgroups of Urothelial Cancer

June 10th 2025

First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.

Elacestrant Combinations in ER+  Breast Cancer | Image Credit: ©  Sebastian Kaulitzki - stock.adobe.com

Elacestrant Displays Potential as Combination Backbone in ER+ Breast Cancer After CDK4/6 Inhibition

June 10th 2025

Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.

Recurrent Low-Grade NMIBC | Image credit: © freshidea - stock.adobe.com

UGN-102 Elicits Nearly 80% CR Rate in Recurrent Low-Grade NMIBC

June 9th 2025

UGN-102 showed strong responses in patients with recurrent, intermediate-risk, low-grade non–muscle-invasive bladder cancer, per the phase 3 ENVISION trial.

 Image by  Ashling Wahner & MJH Life  Sciences Using AI

RET Inhibitor Rechallenge Demonstrates Activity in Previously Treated NSCLC

June 8th 2025

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

Upper Tract Urothelial Cancer | Image credit:   © Sebastian Kaulitzki - stock.adobe.com

Padeliporfin VTP Shows Safety, Clinical Activity in Upper Tract Urothelial Cancer

June 7th 2025

The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.

Muscle-Invasive Bladder Cancer | Image Credit: © maya2008 - stock.adobe.com

Perioperative Sacituzumab Govitecan Plus Pembrolizumab Is Safe, Active in MIBC

June 6th 2025

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

Melanoma | Image Credit:  © Cyber Shutter - stock.adobe.com

RP1 Yields Responses in Deep/Visceral Lesions and Across Injected/Non-Injected Lesions in Advanced PD-1–Refractory Melanoma

June 6th 2025

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Epcoritamab in Relapsed/Refractory LBCL | Image credit: © Bipul Kumar - stock.adobe.com

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL

June 5th 2025

Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.

RCC | Image by Ashling Wahner   & MJH Life Sciences Using AI

Machine Learning–Based Approach Improves Outcome Prediction vs Individual Biomarkers in RCC

June 5th 2025

The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.

JNJ-79635322 in R/R Myeloma | Image Credit: © Nicat - stock.adobe.com

Trispecific Antibody JNJ-79635322 Is Safe and Demonstrates Early Efficacy Signals in R/R Myeloma

June 4th 2025

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

Tivozanib in Metastatic RCC | Image by Ashling Wahner   & MJH Life Sciences Using AI

Single-Agent Tivozanib Shows Activity in Metastatic RCC After Contemporary Frontline Therapy

June 4th 2025

Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.

THIO Plus Cemiplimab in ICI-Resistant Advanced NSCLC | Image by Ashling Wahner & MJH Life Sciences Using AI

THIO Plus Cemiplimab Shows Activity and Is Safe in ICI-Resistant Advanced NSCLC

June 4th 2025

THIO plus cemiplimab showed tolerability and activity in ICI-resistant advanced NSCLC in the second- and third-line settings.

Mesothelioma | Image by Ashling Wahner & MJH Life Sciences Using AI

BNT327/PM8002 Plus Chemo Is Active in Unresectable Pleural and Peritoneal Mesothelioma

June 4th 2025

Frontline BNT327/PM8002 plus chemotherapy was effective and safe in patients with unresectable pleural and peritoneal mesothelioma.

Gastric/GEJ cancer| Image by Ashling Wahner  & MJH Life Sciences Using AI

Fruquintinib Plus Chemotherapy and PD-1 Inhibition Is Safe and Active in Treatment-Naive HER2– Gastric/GEJ Adenocarcinoma

June 4th 2025

Fruquintinib plus chemotherapy and a PD-1 inhibitor was safe and effective in patients with untreated HER2-negative advanced gastric/GEJ cancer.

NXC-201 in relapsed/refractory light chain amyloidosis   | © Oleksandr - stock.adobe.com

NXC-201 CAR T-Cell Therapy Displays Early Activity in Relapsed/Refractory Light Chain Amyloidosis

June 3rd 2025

The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.

High-Risk Resectable Melanoma | Image credit: © Galina - stock.adobe.com

Dostarlimab Plus Cobolimab Improves MPR Rate vs Dostarlimab in High-Risk Resectable Melanoma

June 3rd 2025

Dostarlimab plus cobolimab bested dostarlimab monotherapy in terms of MPR and RFS in patients with high-risk resectable melanoma.

Adjuvant Encorafenib/Binimetinib in BRAF V600–Mutant Melanoma | Image Credit: © Artur - stock.adobe.com

Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma

June 3rd 2025

Adjuvant encorafenib/binimetinib was well tolerated with a manageable toxicity profile in patients with high-risk, stage IIB/C BRAF V600-mutant melanoma.

Dana E. Rathkopf, MD

Dr Rathkopf on the Efficacy of Niraparib Plus Abiraterone Acetate/Prednisone in HRR-Altered mCSPC

June 3rd 2025

Dana E. Rathkopf, MD, discusses the efficacy of niraparib plus abiraterone acetate and prednisone in patients with mCSPC and HRR gene alterations.

Transplant-Ineligible Multiple Myeloma | Image Credit: © TheWaterMeloonProjec - stock.adobe.com

Elranatamab Plus Daratumumab and Lenalidomide Is Active in Transplant-Ineligible Multiple Myeloma

June 3rd 2025

Elranatamab plus daratumumab and lenalidomide was safe and effective in transplant-ineligible patients with newly diagnosed multiple myeloma.

Cervical Cancer | Image Credit: © freshidea - stock.adobe.com

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer

June 3rd 2025

An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

Cilta-Cel in R/R Myeloma | Image credit: © Oleksandr - stock.adobe.com

One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel

June 3rd 2025

A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.